Author pages are created from data sourced from our academic publisher partnerships and public sources.
Top 100 relevant results, sorted by most influential
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Abstract This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care. A "Guidance" document is different from a "Guideline." Guidelines are… Expand
Nonalcoholic fatty liver disease: a systematic review.
- M. Rinella
- 9 June 2015
IMPORTANCE Nonalcoholic fatty liver disease and its subtype nonalcoholic steatohepatitis affect approximately 30% and 5%, respectively, of the US population. In patients with nonalcoholic… Expand
Mechanisms of NAFLD development and therapeutic strategies
There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum of liver abnormalities… Expand
The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance.
BACKGROUND/AIMS Non-alcoholic steatohepatitis is an important disease whose pathophysiology remains incompletely understood, although in humans a strong association with insulin resistance exists.… Expand
Management of NAFLD: a stage-based approach
NAFLD is the most prevalent form of liver disease in the USA, affecting an estimated 30% of the population. The condition is associated with increased mortality related to cardiovascular disease,… Expand
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- Stephen A. Harrison, M. Rinella, M. Abdelmalek, J. Trotter, R. Loomba
- The Lancet
- 24 March 2018
BACKGROUND Non-alcoholic steatohepatitis is a chronic liver disease characterised by the presence of hepatic steatosis, inflammation, and hepatocellular injury, for which no Food and Drug… Expand
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial.
INTRODUCTION The burden of non-alcoholic steatohepatitis (NASH) is growing and current pharmacologic treatments are limited by side effects and inconsistent efficacy. Pilot studies suggest that… Expand
The role of diet and nutrient composition in nonalcoholic Fatty liver disease.
- E. McCarthy, M. Rinella
- Medicine, Biology
- Journal of the Academy of Nutrition and Dietetics
- 1 March 2012
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the developed world. NAFLD is tightly linked to insulin resistance and considered to be the hepatic… Expand
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- Z. Younossi, V. Ratziu, R. Loomba, M. Rinella, Regenerate Study Investigators
- The Lancet
- 5 December 2019
BACKGROUND Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the… Expand
Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events
- L. VanWagner, M. Bhave, H. Te, J. Feinglass, L. Alvarez, M. Rinella
- 1 November 2012
Nonalcoholic steatohepatitis (NASH) is an independent predictor of coronary artery disease (CAD). Our aim was to compare the incidence of cardiovascular (CV) events between patients transplanted for… Expand